SCHEMBL2965430

SCHEMBL2965430

Cc1cn(S(=O)(=O)c2ccccc2)c2ncc(Br)cc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.47
HTR6 P50406 7/20 0.42
ENPP3 O14638 1/20 0.40
ENPP1 P22413 1/20 0.40
DRD2 P14416 3/20 0.39
HTR2A P28223 3/20 0.39
HTR7 P34969 3/20 0.39
CYP3A4 P08684 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2C P28335 1/20 0.39
HRH1 P35367 1/20 0.39
ADRA1B P35368 1/20 0.39
SLC6A3 Q01959 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR1A P08908 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C1 Q04828 1/20 0.38
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956041 0.91 GAA (0.46) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL15882765 0.90 ENPP3 (0.44) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL25255375 0.86 RAPGEF4 (0.40) BRD4HTR6DRD2HTR2AHTR7
SCHEMBL1043519 0.84 BRD4 (0.58) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL1773389 0.84 HTR6 (0.51) BRD4HTR6DRD2HTR2AHTR7
SCHEMBL13620691 0.83 HTR6 (0.53) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL2237476 0.83 LMNA (0.56) BRD4HTR6ENPP3ENPP1PTGDR2
SCHEMBL4196067 0.82 KDM4E (0.45) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL1796808 0.82 AKR1C3 (0.56) BRD4HTR6ENPP3ENPP1DRD2
SCHEMBL4199152 0.81 BRD4 (0.41) BRD4HTR6ENPP3ENPP1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. 2023-09-07 US disclosed
WO-2021013083-A1 TRICYCLIC COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF BEIGENE, LTD. (KY) 2021-01-28 WO disclosed
US-7772246-B2 Pyrazole compounds as RAF inhibitors PFIZER INC. (US) 2010-08-10 US disclosed
EP-2183243-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS Pfizer Inc. (US) 2010-05-12 EP disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 US disclosed
US-20090215771-A1 JNK INHIBITORS GRACZYK PIOTR 2009-08-27 US disclosed
WO-2009016460-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS PFIZER INC. (US) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221608-A1 PYRAZOLE COMPOUNDS BRAF, RAF1, NRAS BRD4 569/4885HTR6 4165/4885ENPP3 2496/4885
US-20230277534-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, PRKACA, MAP3K13 BRD4 741/4885HTR6 3927/4885ENPP3 1733/4885
US-20090215771-A1 JNK INHIBITORS MAPKAPK2, MAPK1, MAPKAPK3 BRD4 1339/4885HTR6 2381/4885ENPP3 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.